The Long Quest to Defeat Alzheimer’s – The State of Dementia Research in 2025
Alzheimer’s disease, the most common form of dementia, poses one of the greatest challenges in modern medicine. Every year,
Recursive Evidence and the Fat-Tailed Risk of HTA Circularity
It begins, as all good policies do, with a peer-reviewed article. A study from 2013 estimates the cost of a
New Funds on the Block: The First-Half Year Check-In on Biotech VC & PE
The first half of 2025 has seen a wave of new venture capital (VC) and private equity (PE) funds dedicated
What Are Drug Targets? A Sceptic’s Guide to Molecular Bullseyes
1. Introduction: The Gospel of the Target
In the parlance of modern pharmaceuticals, few words carry the theological weight of
The Algorithmic Mirage: How AI's Promise in Drug Discovery Risks Inflating Expectations
I. Introduction: The Double-Edged Scalpel of AI in Drug Discovery
The relentless pursuit of new medicines remains a cornerstone of
Magic Bullets, Reloaded: The Global Rise of Antibody–Drug Conjugates
The Return of the “Magic Bullet”
In 1908, the German scientist Paul Ehrlich coined the term “Zauberkugel” – magic bullet – envisioning
Pharma’s Perennial Patent Cliff: Crisis or Routine Cycle?
The Next Big Patent Cliff Looms
Pharmaceutical investors are once again bracing for what industry insiders ominously dub a “patent
Royalty Financing Rescues Biopharma: A H1 2025 Global Analysis
The first half of 2025 saw an unprecedented surge in royalty-based financings and structured revenue deals across the biopharmaceutical sector.
High Ideals, Inside Deals: Biotech’s Lab Leaks of the Financial Kind
Trials, Errors, and Timely Trades
In the rarefied world of biotech, miracles in the lab often meet murkier practices in
THE PANEL DISCUSSION FROM HELL
A Corporate Pastoral in Four Acts
By one who has seen the lanyards and despaired.
DRAMATIS PERSONAE
* CLAIRE DU VAGUE
